No products in the cart.
Pre-made Eramkafusp benchmark antibody ( Whole mAb Fusion, anti-MS4A1/CD20 therapeutic antibody, Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-192
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Eramkafusp biosimilar, Whole mAb Fusion, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Products Name (INN Index) | Pre-Made Eramkafusp biosimilar, Whole mAb Fusion, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody |
|---|---|
| INN Name | Eramkafusp |
| Target | CD20 |
| Format | Whole mAb Fusion |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | 2osl:AB:HL/4kaq:HL |
| 95-98% SI Structure | None |
| Year Proposed | 2020 |
| Year Recommended | NA |
| Companies | Spectrum Pharmaceuticals,ImmunGene |
| Conditions Approved | NA |
| Conditions Active | Non-Hodgkin's lymphoma |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD20 |
| Package |
Previous slide
Next slide
